Loading…
Employees: 196
Size 4D Molecular Therapeutics (FDMT) is a United States Health Care company (Biotechnology) with a market value of $677M, the 2509th largest of 3,117 United States companies the cockpit tracks. Shares closed at $12.25 on 6 Nov 2026.
Performance Over six months the shares gained 20.8%, against -22.0% for the median peer and -1.1% for the United States market (cap-weighted) — 2nd highest of 19 in its peer set.
Growth Revenue grew 278,712.1% over the last twelve months (peer median +13.3%); the operating margin is -214.2% (peer median -92.0%).
Valuation It trades at 3.9× enterprise value to sales against a peer median of 4.7× (5th cheapest of 14).
Capital Return on invested capital runs 200.7 points below its cost of capital (18.6% WACC).
Short interest Short interest is 20.9% of the free float (15 Oct 2026).
Next results Next results expected around 11 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $92.0M | $85.2M | $37,000 | $20.7M | $3.13M |
| Revenue growth | — | +230,195% | -100% | +562% | — |
| Gross profit | $83.9M | $77.6M | -$6.67M | $15.0M | -$751,000 |
| EBITDA | -$189M | -$152M | -$181M | -$107M | -$106M |
| Net income | -$179M | -$140M | -$161M | -$101M | -$107M |
| Free cash flow | -$156M | -$110M | -$138M | -$78.6M | -$98.2M |
| Capital expenditure | -$106,000 | $536,000 | $3.79M | $2.77M | $11.5M |
| Total debt | $39.2M | $21.4M | $24.6M | $14.7M | $16.1M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | FDMT | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -3.5% | -10.5% | 6th highest of 21 |
| 6-month return | +20.8% | -22.0% | 2nd highest of 19 |
| Distance from 52-week high | -27.6% | -44.7% | 3rd highest of 21 |
| Revenue growth (TTM) | +278,712.1% | +13.3% | highest of 13 |
| Operating margin | -214.2% | -92.0% | 5th lowest of 14 |
| EV / Sales | 3.9× | 4.7× | 5th cheapest of 14 |
| ROIC minus cost of capital | -200.7 pp | -15.2 pp | lowest of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| 4D Molecular Therapeutics FDMT | United States | $677M | +21% | +278,712% | -214% | 3.9× | n/a | n/a |
| Aura Biosciences AURA | United States | $680M | -22% | n/a | n/a | n/a | n/a | n/a |
| Shenzhen Weiguang Biological Products 002880.SZ | China | $682M | -22% | 0% | 18% | 4.7× | n/a | n/a |
| Candel Therapeutics CADL | United States | $670M | +5% | n/a | n/a | n/a | n/a | n/a |
| Anhui Huaheng Biotechnology 688639.SS | China | $688M | -40% | +7% | 3% | 2.1× | n/a | n/a |
| Boji Medical Technology 300404.SZ | China | $664M | +7% | +32% | 4% | 4.1× | 35.4% | +27.2% |
| Wave Life Sciences WVE | United States | $664M | -53% | -35% | -321% | 3.9× | n/a | n/a |
| Attovia Therapeutics ATTO | United States | $697M | +744% | n/a | -4,975% | 625.6× | n/a | n/a |
| Solid Biosciences SLDB | United States | $707M | -9% | n/a | n/a | n/a | n/a | n/a |
| Getein Biotech 603387.SS | China | $647M | -12% | +8% | 21% | 2.7× | -8.3% | -1.3% |
| Kura Oncology KURA | United States | $647M | -23% | -7% | -412% | 2.0× | n/a | n/a |
| Sana Biotechnology SANA | United States | $709M | -32% | n/a | n/a | n/a | n/a | n/a |
| Design Therapeutics DSGN | United States | $639M | -28% | n/a | n/a | n/a | n/a | n/a |
| Geron GERN | United States | $636M | -29% | +19% | -8% | 1.6× | n/a | n/a |
| Shouyao Holdings Beijing 688197.SS | China | $726M | -16% | +4,564% | -92% | 43.1× | n/a | n/a |
| Apnimed APMD | United States | $629M | n/a | +380% | -140% | 20.3× | n/a | n/a |
| Frontier Biotechnologies 688221.SS | China | $746M | -37% | +153% | -20% | 13.1× | 43.2% | +21.5% |
| Ascletis Pharma 1672.HK | Hong Kong | $610M | -73% | -59% | -71,976% | 2,088.7× | n/a | n/a |
| Genfit GNFT.PA | France | $593M | +19% | +28% | -130% | 11.2× | 40.0% | +143.5% |
| Climb Bio CLYM | United States | $591M | -10% | n/a | n/a | n/a | n/a | n/a |
| Shaanxi Micot Pharmaceutical Technology 2335.HK | Hong Kong | $777M | n/a | n/a | n/a | n/a | n/a | n/a |